Effectiveness of Mass Drug Administration for Reducing Seasonal Malaria Transmission in Zanzibar

• Status: Completed
• Trial end date: 2017-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The overall aim of this study is to determine the effectiveness of two rounds of mass drug administration (MDA) with dihydroartemisinin-piperaquine (DHAp) + single low dose (SLD) primaquine for reducing seasonal malaria transmission in Shehias considered hotspots on Unguja Island, Zanzibar.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ulrika Morris
• Collaborators: Mahidol Oxford Tropical Medicine Research Unit; RTI International; The President's Malaria Initiative; The President’s Malaria Initiative; University of California, San Francisco; Uppsala University; Zanzibar Malaria Control Programme; Zanzibar Malaria Elimination Programme
• Treatments: Artemisinins; Artenimol; Dihydroartemisinin; Piperaquine; Primaquine

Criteria

Inclusion Criteria:

• Permanent or temporary resident of study Shehias (i.e., persons who stayed in the selected household the night before the interview)

• Provision of informed consent (refusal must be recorded)

• Age >6 months

Exclusion Criteria:

• Women pregnant in first trimester (assessed by a specific set of questions designed to exclude pregnancy)

• Severe disease that requires immediate referral to health facility or hospital

• Concurrent antimalarial treatment at time of MDA or during the last 14 days

• Inability to take oral medication

Additional exclusion criteria for treatment with SLD Primaquine:

• Pregnancy (all trimesters, assessed by a specific set of questions designed to exclude pregnancy)

• Women breast feeding infants aged < 6months